Early Signals of the Transition From Immune Quiescence to Activation in the Liver Allograft Microenvironment and in the Circulation
This is a prospective multi-center, longitudinal study to determine efficacy of 50 percent Immunosuppression (IS) reduction. One hundred fully eligible participants will reduce IS by 50 percent in two steps. Liver tests will be checked every 0.5 months through month 4, ...
Age: 3 - 13 years
Gender: All
Liver Transplant CGM
This investigator initiated study aims to describe continuous glucose monitoring (CGM)
based glycemic metrics after discharge from liver transplant and assess relationship with
glycemic metrics and liver transplant outcomes.
Age: 18 years - 66+
Gender: All
Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant
A single institution, single arm, two-cohort feasibility trial to evaluate the
combination of locoregional Y^90 therapy with systemic atezolizumab and bevacizumab, in
participants presenting with hepatocellular carcinoma (HCC) 1) within Milan Criteria (MC)
with AFP ≥...
Age: 18 years - 66+
Gender: All
Guerbet Liver Fibrosis
The goal of this study is to assess the value of liver dynamic contrast-enhanced magnetic
resonance imaging (DCE-MRI) and texture analysis post gadopiclenol for liver fibrosis
staging, in comparison with MR elastography, T1 mapping, ultrasound elastography and
blood ...
Age: 18 - 89 years
Gender: All
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
This study is open to adults who are at least 18 years old living with obesity and have:
- a confirmed liver disease called non-alcoholic steatohepatitis (NASH)/metabolic
associated steatohepatitis (MASH) and
- moderate or advanced liver fibrosis
People wit...
Age: 18 years - 66+
Gender: All
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
This study is open to adults who are at least 18 years old and have:
- A confirmed liver disease called non-alcoholic steatohepatitis (NASH) or
- A confirmed liver disease called metabolic-associated steatohepatitis (MASH)
- BMI of 27 kg/m2 or more or
- ...
Age: 18 years - 66+
Gender: All
High Fructose Diet, the Gut Microbiome, and Metabolic Health
Americans commonly consume excess amounts of dietary fructose. Added fructose has been
shown to have an adverse impact on metabolic health, including increased insulin
resistance and type 2 diabetes (T2D) risk. However, the mechanisms that link dietary
fructose and m...
Age: 25 - 45 years
Gender: All
Expanding Liver Transplant Immunosuppression Minimization Via Everolimus
This is a study to determine the safety, efficacy, and tolerability of taking away the
anti-rejection medicine, tacrolimus, in liver transplant recipients in conjunction with
everolimus monotherapy to preserve renal function. Two hundred - seventy (270) subjects
will...
Age: 18 years - 66+
Gender: All
An Open-label Study to Investigate ECUR-506 in Male Babies Less Than 9 Months of Age With Neonatal Onset OTC Deficiency
Ornithine Transcarbamylase (OTC) deficiency, the most common urea cycle disorder, is an
inherited metabolic disorder caused by a genetic defect in a liver enzyme responsible for
detoxifying of ammonia. Individuals with OTC deficiency can develop elevated levels of
am...
Age: 24 hours - 7 months
Gender: Male
A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis
The purpose of this study is to assess the safety of atezolizumab and bevacizumab, or
atezolizumab alone, as first-line treatment in participants with unresectable, locally
advanced or metastatic hepatocellular carcinoma (HCC) with Child-pugh B7 or B8 cirrhosis.
Age: 18 years - 66+
Gender: All
A Study of NST-6179 in Subjects With Intestinal Failure-Associated Liver Disease (IFALD).
This is a phase 2a, multicenter, randomized, double-blind, placebo-controlled study to
evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of
NST-6179 in subjects with intestinal failure-associated liver disease (IFALD) receiving
paren...
Age: 16 years - 66+
Gender: All
ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk
The primary objective is to assess overall sensitivity and specificity of Oncoguard™
Liver for hepatocellular cancer (HCC) detection in a surveillance population.
Age: 18 years - 66+
Gender: All
Bridge to HOPE: Hypothermic Oxygenated Perfusion Versus Cold Storage Prior to Liver Transplantation
This is a prospective, multi-center, controlled, randomized, pivotal study to evaluate the
safety and effectiveness of the VitaSmart Liver Machine Perfusion System by comparing
clinical outcomes in patients undergoing liver transplantation with ex-vivo liver
prese...
Age: 18 years - 66+
Gender: All
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
A 52-Week, Multi-center, Open-label, Active Treatment Extension Study to Evaluate Safety and
Tolerability of Once Daily, Oral Administration of Resmetirom (MGL-3196)
Age: 18 years - 66+
Gender: All
TReatment for ImmUne Mediated PathopHysiology
TReatment for ImmUne Mediated PathopHysiology (TRIUMPH) is a multi-center, three arm,
randomized, controlled trial of immunosuppressive therapy for children with acute liver
failure. The study will determine if suppressing inflammatory responses with either
corticost...
Age: 1 year - 18 years
Gender: All
Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs
Management of ACLF is mainly supportive. The poor outcomes lead physicians to consider
liver transplantation as an option, even if controversial. In sicker recipients, LT
results in immediate survival, but poor medium-term survival rates in some studies. The
scarcity...
Age: 18 - 80 years
Gender: All
Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study
This phase II trial investigates how well lisinopril may work in preventing the
progression of non-alcoholic fatty liver disease (NAFLD). NAFLD is a condition where
there is an accumulation of fatty cells in the liver. NAFLD increases a person's risk of
developing li...
Age: 18 years - 66+
Gender: All
Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study
This phase II trial investigates how well lisinopril may work in preventing the progression of non-alcoholic fatty liver disease (NAFLD). NAFLD is a condition where there is an accumulation of fatty cells in the liver. NAFLD increases a person's risk of developing liver...
Age: 18 years - 66+
Gender: All
FAST (Focused Abbreviated Screening Technique)-MRI Study
The purpose of this study is to compare the diagnostic value of a reconstructed
abbreviated Magnetic Resonance Imaging (MRI) from a full clinical exam, compared to
ultrasound (US) for screening of liver cancer. Blood markers will be evaluated to
determine their corre...
Age: 18 years - 66+
Gender: All
Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
To evaluate, in patients with suspected NASH referred for liver biopsy, the diagnostic
performance of CT1 at discriminating those with NAS≥4 & F≥2 from those without.
Age: 18 - 75 years
Gender: All